Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen to launch biosimilar of Regeneron's Eylea after U.S. appeals court ruling in its favor.
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030
The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.
Three-year Results for EYLEA HD® (aflibercept) Injection 8
88% of EYLEA HD patients maintained ≥12-week dosing intervals at week 156, sustaining visual and anatomic improvements. EYLEA HD showed slower fluid reaccumulation and longer duration of action compared to EYLEA. Safety data remained consistent with known profiles.
Patient, Care Partner, and Physician Voices in Treatment Decision-Making
Study on MM treatment decision-making highlights QoL, duration of response, and side effects as top attributes for patients, care partners, and physicians. Differences in preferences and trade-offs underscore the importance of shared decision-making (SDM) to align treatment plans with patient values and improve outcomes.
COPD market expected to grow to $30.8bn in the 7MM by 2033
The COPD market in the 7MM is projected to grow from $11.5bn in 2023 to $30.8bn in 2033, driven by recent approvals like Sanofi/Regeneron’s Dupixent and anticipated pipeline agents. Biologics targeting moderate-to-severe exacerbators show promise, with Dupixent expected to reach $6.57bn by 2033. Late-stage pipeline products, including AstraZeneca’s Fasenra and GSK’s Nucala, aim to address unmet needs, while GSK’s Trelegy Ellipta is expected to grow to $2.16bn by 2033. Potential barriers include loss of exclusivity and the $35 inhaler cap in the US.
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
AstraZeneca's Farxiga, initially approved for type 2 diabetes, has exceeded $6 billion in sales and is projected to reach $7.4 billion next year. Success factors include addressing unmet needs, clear value propositions, and strategic market access. Farxiga expanded its indications to chronic kidney disease and heart failure, driving sales. Keytruda exemplifies a blockbuster drug with multiple indications. Market access strategies and pricing considerations are crucial for drug commercialization. The definition of a blockbuster is evolving, focusing on high-value drugs that justify R&D investments.
Alnylam seeks EMA nod for heart-related therapy
Alnylam Pharmaceuticals submitted a regulatory application to the EMA for vutrisiran to treat ATTR-CM, based on the positive HELIOS-B Phase 3 study. The drug, already approved for hATTR amyloidosis, targets the TTR gene, showing significant reduction in death and cardiovascular events. Alnylam also submitted an sNDA to the FDA for vutrisiran and plans further global submissions.
Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
Regeneron loses bid to block Amgen's Eylea biosimilar, plans appeal; Prime Therapeutics adds low-cost Humira biosimilars; FDA and EMA accept Alvotech's denosumab biosimilar for review.
Regeneron and Sanofi's Dupixent Tipped to Dominate COPD Biologics Market
Regeneron and Sanofi won FDA approval for Dupixent in COPD, targeting 300,000 U.S. adults with eosinophilic phenotype. GlobalData forecasts $6.57 billion in 2033 sales, while Sanofi and BMO Capital Markets predict $5.5 billion and $2.5 billion respectively. Competitors AstraZeneca, GSK, and Roche have ongoing trials for their biologics in COPD. Regeneron and Sanofi aim to establish market presence before rivals launch.
GSK says antibody drug succeeds in testing for chronic nasal condition
GSK reported positive Phase 3 trial results for depemokimab in chronic rhinosinusitis with nasal polyps, following earlier success in asthma trials. The drug, targeting IL-5, showed significant reduction in nasal polyp growth and obstruction. GSK anticipates peak annual sales of over 3 billion pounds if approved.
© Copyright 2024. All Rights Reserved by MedPath